Market By Device Type, Route Of Administration, End-user, And Country | Forecast 2019-2028
• Canada
• The United States
Countries in the North American region are have reached far ahead in terms of technology adoption, as compared to other countries in the world. They have an advanced healthcare infrastructure and are known to invest heavily in healthcare; therefore, this market accounts for the highest revenue in the global market for injectable drug delivery. As per the National Institute of Health (NIH), around 23.5 million Americans were found to be affected by the autoimmune disease in 2017. And this number is steadily on the rise. Most biologic drugs used for treating these conditions are administered using injectable drug delivery devices. Thus, the rise in the prevalence of autoimmune diseases is propelling the market growth in the United States.
Of late, biologic medications have been receiving approvals from regulatory authorities and are increasingly being commercialized. This has increased the demand for self-injection devices in the country. The National Health Council states that chronic diseases are the leading cause of disability and death in the US, accounting for 7 out of every 10 deaths, and killing over 1.7 million Americans each year. Furthermore, the geriatric population in the country is surging. The US’ Census Bureau predicts the country’s older population to reach 80 million by 2050. Older adults are more prone to diseases and infections, and they prefer self administration to visit a healthcare facility for drug administration. Therefore, the increase in cases of chronic diseases and the rise in the elderly population are enhancing the demand for injectable drug delivery devices.
Eli Lilly and Company is engaged in developing, manufacturing, and marketing pharmaceutical products and animal health products. In the field of injectable drug delivery, it offers solutions such as BASAGLAR, Humalog, and GLYXAMBI. The US-based company is headquartered in Indianapolis, Indiana. With strong R&D capabilities, the company is looking to expand its footprint globally.
Market By Type, Application, E ..
VIEW REPORT
Market By Device Type, Therape ..
VIEW REPORT
Market By Type, Application, T ..
VIEW REPORT
Market By Technology, Applicat ..
VIEW REPORT
Market By Application, Type, E ..
VIEW REPORT
Market by Therapeutics, Diagno ..
VIEW REPORT
Market by Type, Application, E ..
VIEW REPORT1. NORTH AMERICA INJECTABLE DRUG DELIVERY MARKET - SUMMARY
2. INDUSTRY OUTLOOK
2.1. MARKET DEFINITION
2.2. PORTER’S FIVE FORCES MODEL
2.2.1. THREAT OF NEW ENTRANT
2.2.2. THREAT OF SUBSTITUTE
2.2.3. BARGAINING POWER OF BUYERS
2.2.4. BARGAINING POWER OF SUPPLIERS
2.2.5. INTENSITY OF COMPETITIVE RIVALRY
2.3. KEY INSIGHT
2.4. KEY BUYING CRITERIA
2.5. REGULATORY FRAMEWORK
2.6. MARKET ATTRACTIVENESS INDEX
2.7. MARKET DRIVERS
2.7.1. INCREASING GERIATRIC POPULATION
2.7.2. TECHNOLOGICAL ADVANCEMENT
2.7.3. GROWING OCCURRENCE OF AUTOIMMUNE DISEASES
2.8. MARKET RESTRAINTS
2.8.1. HIGH MANUFACTURING COST OF INJECTABLE DRUG DELIVERY SYSTEMS
2.9. MARKET OPPORTUNITIES
2.9.1. DEVELOPMENT OF BETTER INJECTABLE SYSTEMS
2.9.2. INCREASE IN HEALTHCARE EXPENDITURE
2.10. MARKET CHALLENGES
2.10.1. DEVELOPMENTS IN ALTERNATE DRUG DELIVERY SYSTEMS
2.10.2. STRINGENT REGULATIONS
3. INJECTABLE DRUG DELIVERY MARKET OUTLOOK - BY DEVICE TYPE
3.1. PEN INJECTOR
3.2. AUTO-INJECTOR
3.3. NEEDLE-FREE INJECTOR
3.4. PREFILLED SYRINGE
4. INJECTABLE DRUG DELIVERY MARKET OUTLOOK - BY ROUTE OF ADMINISTRATION
4.1. SUBCUTANEOUS
4.2. INTRAMUSCULAR
4.3. INTRAVENOUS (IV)
4.4. OTHER ROUTE OF ADMINISTRATION
5. INJECTABLE DRUG DELIVERY MARKET OUTLOOK - BY END-USER
5.1. CLINICS/ PHYSICIAN OFFICES
5.2. AMBULATORY CARE
5.3. HOSPITAL
5.4. HOME-BASED
5.5. OTHER END-USERS
6. INJECTABLE DRUG DELIVERY MARKET – NORTH AMERICA
6.1. COUNTRY ANALYSIS
6.1.1. THE UNITED STATES
6.1.2. CANADA
7. COMPANY PROFILES
7.1. BAXTER INTERNATIONAL INC
7.2. BECTON DICKINSON AND COMPANY (BD)
7.3. ELCAM MEDICAL
7.4. ELI LILLY AND COMPANY
7.5. GERRESHEIMER
7.6. INJEX
7.7. NOVARTIS AG
7.8. NOVO NORDISK A/S
7.9. PFIZER INC
7.10. SANOFI SA
7.11. SCHOTT AG
7.12. TERUMO CORPORATION
7.13. TEVA PHARMACEUTICALS
7.14. WEST PHARMACEUTICALS
7.15. YPSOMED HOLDING AG
8. RESEARCH METHODOLOGY & SCOPE
8.1. RESEARCH SCOPE & DELIVERABLES
8.1.1. OBJECTIVES OF STUDY
8.1.2. SCOPE OF STUDY
8.2. SOURCES OF DATA
8.2.1. PRIMARY DATA SOURCES
8.2.2. SECONDARY DATA SOURCES
8.3. RESEARCH METHODOLOGY
8.3.1. EVALUATION OF PROPOSED MARKET
8.3.2. IDENTIFICATION OF DATA SOURCES
8.3.3. ASSESSMENT OF MARKET DETERMINANTS
8.3.4. DATA COLLECTION
8.3.5. DATA VALIDATION & ANALYSIS
TABLE 1 NORTH AMERICA INJECTABLE DRUG DELIVERY MARKET, BY REGION, 2019-2028 ($ MILLION)
TABLE 2 NORTH AMERICA INJECTABLE DRUG DELIVERY MARKET, BY DEVICE TYPE, 2019-2028 ($ MILLION)
TABLE 3 DIFFERENT TYPES OF INSULIN PEN INJECTORS
TABLE 4 MARKETED NEEDLE-FREE INJECTORS PRODUCTS
TABLE 5 LYOPHILIZED DRUGS WHICH ARE USED IN PREFILLED SYRINGE
TABLE 6 NORTH AMERICA INJECTABLE DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 ($ MILLION)
TABLE 7 NORTH AMERICA INJECTABLE DRUG DELIVERY MARKET, BY END-USER, 2019-2028 ($ MILLION)
TABLE 8 NORTH AMERICA INJECTABLE DRUG DELIVERY MARKET, BY COUNTRY, 2019-2028 ($ MILLION)
FIGURE 1 NORTH AMERICA INJECTABLE DRUG DELIVERY MARKET 2019-2028 ($ MILLION)
FIGURE 2 KEY BUYING IMPACT ANALYSIS
FIGURE 3 NORTH AMERICA INJECTABLE DRUG DELIVERY MARKET, BY PEN INJECTOR, 2019-2028 ($ MILLION)
FIGURE 4 NORTH AMERICA INJECTABLE DRUG DELIVERY MARKET, BY AUTO-INJECTOR, 2019-2028 ($ MILLION)
FIGURE 5 NORTH AMERICA INJECTABLE DRUG DELIVERY MARKET, BY NEEDLE-FREE INJECTOR, 2019-2028 ($ MILLION)
FIGURE 6 NORTH AMERICA INJECTABLE DRUG DELIVERY MARKET, BY PREFILLED, 2019-2028 ($ MILLION)
FIGURE 7 NORTH AMERICA INJECTABLE DRUG DELIVERY MARKET, BY SUBCUTANEOUS, 2019-2028 ($ MILLION)
FIGURE 8 NORTH AMERICA INJECTABLE DRUG DELIVERY MARKET, BY INTRAMUSCULAR , 2019-2028 ($ MILLION)
FIGURE 9 NORTH AMERICA INJECTABLE DRUG DELIVERY MARKET, BY INTRAVENOUS , 2019-2028 ($ MILLION)
FIGURE 10 NORTH AMERICA INJECTABLE DRUG DELIVERY MARKET, BY OTHER ROUTE OF ADMINISTRATION, 2019-2028 ($ MILLION)
FIGURE 11 NORTH AMERICA INJECTABLE DRUG DELIVERY MARKET, BY CLINICS/PHYSICIAN OFFICES, 2019-2028 ($ MILLION)
FIGURE 12 NORTH AMERICA INJECTABLE DRUG DELIVERY MARKET, BY AMBULATORY CARE, 2019-2028 ($ MILLION)
FIGURE 13 NORTH AMERICA INJECTABLE DRUG DELIVERY MARKET, BY HOSPITAL, 2019-2028 ($ MILLION)
FIGURE 14 NORTH AMERICA INJECTABLE DRUG DELIVERY MARKET, BY HOME-BASED, 2019-2028 ($ MILLION)
FIGURE 15 NORTH AMERICA INJECTABLE DRUG DELIVERY MARKET, BY OTHER END-USER, 2019-2028 ($ MILLION)
FIGURE 16 THE UNITED STATES INJECTABLE DRUG DELIVERY MARKET 2019-2028 ($ MILLION)
FIGURE 17 CANADA INJECTABLE DRUG DELIVERY MARKET 2019-2028 ($ MILLION)